ReviewVascular health and risk management2007

Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme.

Luis Miguel Ruilope et al.PubMed ↗Full text ↗

No numbers read from the abstract.